We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Terns Pharmaceuticals launched with $30mm Series A from Lilly Asia
06 Apr 2018
Executive Summary
Terns Pharmaceuticals Inc. raised $30mm in Series A funding from Lilly Asia Ventures. The company was recently launched and is developing molecularly-targeted oral small-molecule candidates for liver diseases (including nonalcoholic steatohepatitis) and cancer. Terns is based in California and Shanghai, and intends to initially focus its drug development efforts on unmet medical needs in China.
Deal Industry
Biotechnology
Pharmaceuticals
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?